Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00451516
Registration number
NCT00451516
Ethics application status
Date submitted
22/03/2007
Date registered
23/03/2007
Date last updated
19/05/2008
Titles & IDs
Public title
St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety
Query!
Scientific title
St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety
Query!
Secondary ID [1]
0
0
2006000925
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Depressive Disorder, Major
0
0
Query!
Anxiety Disorders
0
0
Query!
Condition category
Condition code
Mental Health
0
0
0
0
Query!
Anxiety
Query!
Mental Health
0
0
0
0
Query!
Depression
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Herbal medicine (St. John's wort and Kava)
Treatment: Drugs: Herbal medicine (St. John's wort and Kava)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
BDI II
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Primary outcome [2]
0
0
BAI
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Query!
Primary outcome [3]
0
0
DASS
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Query!
Secondary outcome [1]
0
0
WHOQOL
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [2]
0
0
Daily Mood Monitoring Form
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
- Any person male or female aged 18-65 presenting with a diagnosis of unipolar
depression confirmed by CIDI auto (quantified by BDI) and an anxiety score on the DASS
of 8 or above i.e. the mean (quantified also by BAI)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- Psychotic/ Bipolar illness
- Current or < 6 month significant suicidal ideation
- Diagnosed hepato-biliary disease/inflammation
- Current or < 6 month substance abuse disorder including alcohol
- Current or < 12 month use of kava, St. John's wort,
- Current or < 1 month of synthetic antidepressants or benzodiazepines
- Previous reaction to kava or St. John's wort
- Medications that maybe pharmacokinetically altered via St. John's wort including:
- Amitriptyline anti-coagulants e.g. phenprocoumon, warfarin,
- Anti-fugals e.g. voriconazole,
- Anti-histamines e.g. fexofenadine,
- Benzodiazepines e.g. alprazolam,
- Chemotherapeutics e.g. irinotecan, digoxin, HIV medication (anti-retrovirals), *
Immunosuppressants e.g. cyclosporine, methadone, OCP,
- Statins e.g. simvastatin, warfarin (Henderson 2002; Izzo 2004).
- However this interactions are based on case studies and theoretical interactions
and are regarded to be induced by hyperforin (a constituent of St. John's wort);
low or non-standardised hyperforin preparations are regarded to not induce drug
interactions as little induction of P-glycoprotein and CYP P450 enzymes occurs
(Madabushi et al. 2006). Although in vitro studies have confirmed that kava and
the isolated kavalactones modulate certain CYP 450 enzymes, no documented
evidence of human kava-drug pharmacokinetic interactions exists (Mathews,
Etheridge & Black 2002; Singh 2005)
- Seeing a psychologist or counsellor currently or in the previous month.
- Non-English speakers.
- Pregnancy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2007
Query!
Sample size
Target
50
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
0
0
RBWH - Brisbane
Query!
Recruitment postcode(s) [1]
0
0
4006 - Brisbane
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
The University of Queensland
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
SJW has the greatest evidence of herbal medicine efficacy in treating MDD. In treating
anxiety, kava has the greatest evidence of efficacy. As comorbidity of MDD and anxiety
commonly occurs, it is conceivable that a combination of an established antidepressant agent
such as SJW and an established anxiolytic agent such as kava may effectively treat MDD
presenting with comorbid anxiety. It is possible that a beneficial synergistic effect may
also occur between SJW and kava, improving the treatment outcomes in MDD with comorbid
anxiety, than by the individual substances alone. Determination of this is not addressed in
this study due to limitations of time and resources. The determination of the strength of the
SJW-kava combination will be ascertained by comparing similar trials using SJW and kava
mono-therapy in addressing MDD and GAD.
The hypothesis is that a combination of SJW and kava will reduce MDD occurring with comorbid
anxiety more than placebo.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00451516
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Jerome Sarris, BHSc
Query!
Address
0
0
The University of Queensland
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00451516
Download to PDF